The Price is Right? – Delivering UK access for niche patient populations

With challenges to highly priced rare disease medicines and the Cancer Drug Fund evolving again – what is next, what are the ramifications for high priced/innovative treatments delivering beneficial outcomes to defined patient populations in the UK and how can pharma navigate seemingly choppy waters of access for rare disease treatments and orphan drugs? Working in partnership with IMS Health, pharmaphorum has assembled an expert panel including NHS England’s Malcolm Qualie, Alan Kane of Shire Pharmaceuticals, Angela McFarlane of IMS Health, the Cystic Fibrosis Trust's Nick Medhurst and pharmaphorum’s own Paul Tunnah to present and debate around these issues in a free to attend one hour webinar. This event will cover: • Access, in the UK, to higher priced drugs/innovative treatments • Rare Disease/Orphan Drug access in the UK • The evolution of the Cancer Drugs Fund - what does this look like, what could it mean for pharma/healthcare It will also enable frank discussion around the new NHS England processes.